Pharmacotherapy of alcohol use disorders and concurrent psychiatric disorders: A review

Canadian Journal of Psychiatry

Volumn 57, Issue 6, 2012, Pages 342-349

  Lev Ran, Shaul ^a   Balchand, Kam ^a   Lefebvre, Lisa ^a,b   Araki, Keyghobad Farid ^a,b   Le Foll, Bernard ^a,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcohol; Concurrent disorders; Medications; Pharmacotherapy; Psychiatric disorders; Use disorders

Indexed keywords

ACAMPROSATE; ALCOHOL; BACLOFEN; BUSPIRONE; CLOZAPINE; DESIPRAMINE; DISULFIRAM; FLUOXETINE; FLUPENTIXOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; NALTREXONE; NEFAZODONE; OLANZAPINE; PAROXETINE; PRAZOSIN; QUETIAPINE; SERTRALINE; TOPIRAMATE; VALPROIC ACID;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL USE DISORDER; ALCOHOLISM; ANXIETY DISORDER; BIPOLAR DISORDER; COMORBIDITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EPILEPSY; HUMAN; HYPERTENSION; MAJOR DEPRESSION; MENTAL DISEASE; MOOD DISORDER; PREVALENCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA;

EID: 84871144806     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/070674371205700603     Document Type: Review

References (78)

1. Grant B, Stinson F, Dawson D, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004;61:807-816. (Pubitemid 39031120)
2. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 1997;54:313-321. (Pubitemid 27171916)
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518.
4. Farrell M, Howes S, Bebbington P, et al. Nicotine, alcohol and drug dependence and psychiatric comorbidity. Results of a national household survey. Br J Psychiatry. 2001;179:432-437. (Pubitemid 33097166)
5. Hasin DS, Stinson FS, Ogburn E, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:830-842. (Pubitemid 47026379)
6. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35 Suppl:S93-S100. (Pubitemid 29133030)
7. Hasin D, Goodwin R, Stinson F, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62:1097-1106. (Pubitemid 41396935)
8. Kessler RC, Nelson CB, McGonagle KA, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;(30):17-30. (Pubitemid 26000488)
9. Rush B, Urbanoski K, Bassani D, et al. Prevalence of co-occurring substance use and other mental disorders in the Canadian population. Can J Psychiatry. 2008;53:800-809.
10. Galanter M, Castaneda R, Ferman J. Substance abuse among general psychiatric patients: place of presentation, diagnosis, and treatment. Am J Drug Alcohol Abuse. 1988;14:211-235.
11. Rush B, Koegl CJ. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psychiatry. 2008;53:810-821.
12. Brooner RK, King VL, Kidorf M, et al. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80. (Pubitemid 27044701)
13. Hien D, Zimberg S, Weisman S, et al. Dual diagnosis subtypes in urban substance abuse and mental health clinics. Psychiatr Serv. 1997;48:1058-1063. (Pubitemid 27329960)
14. Cornelius JR, Bukstein O, Salloum I, et al. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003;16:361-374.
15. Cornelius JR, Salloum IM, Mezzich J, et al. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatry. 1995;152:358-364.
16. Kranzler HR, Rosenthal RN. Dual diagnosis: alcoholism and co-morbid psychiatric disorders. Am J Addict. 2003;12(Suppl 1):S26-S40. (Pubitemid 36583414)
17. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717-734. (Pubitemid 28443188)
18. Woody G. The challenge of dual diagnosis. Alcohol Res Health. 1996;20:76-80. (Pubitemid 126698326)
19. Goldstein BI, Diamantouros A, Schaffer A, et al. Pharmacotherapy of alcoholism in patients with co-morbid psychiatric disorders. Drugs. 2006;66:1229-1237. (Pubitemid 44050437)
20. Health Canada; Rush B, principal author. Best practice for concurrent mental health and substance use disorders. Ottawa (ON): Health Canada; 2001. Catalogue number: H39-599/2001-2E. ISBN: 0-662-31388-7.
21. Schuckit MA, Tipp JE, Anthenelli RM, et al. Anorexia nervosa and bulimia nervosa in alcohol-dependent men and women and their relatives. Am J Psychiatry. 1996;153:74-82. (Pubitemid 26026161)
22. Murphy GE. Suicide in alcoholism. New York (NY): Oxford University Press; 1992.
23. Verheul R, Kranzler HR, Poling J, et al. Axis I and Axis II disorders in alcoholics and drug addicts: fact or artifact? J Stud Alcohol. 2000;61:101-110. (Pubitemid 30005065)
24. LaBounty LP, Hatsukami D, Morgan SF, et al. Relapse among alcoholics with phobic and panic symptoms. Addict Behav. 1992;17:9-15.
25. Pickens RW, Hatsukami DK, Spicer JW, et al. Relapse by alcohol abusers. Alcohol Clin Exp Res. 1985;9:244-247. (Pubitemid 15011400)
26. Svanum S, McAdoo WG. Predicting rapid relapse following treatment for chemical dependence: a matched-subjects design. J Consult Clin Psychol. 1989;57:222-226. (Pubitemid 20079798)
27. Hodgins DC, el-Guebaly N, Armstrong S. Prospective and retrospective reports of mood states before relapse to substance use. J Consult Clin Psychol. 1995;63:400-407.
28. Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589-608. (Pubitemid 28524628)
29. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26:290-302. (Pubitemid 43804621)
30. O'Brien CP, Volpicelli LA, Volpicelli JR. Naltrexone in the treatment of alcoholism: a clinical review. Alcohol. 1996;13:35-39. (Pubitemid 26061201)
31. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
32. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
33. Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2005;(1):CD001867.
34. Anton RF. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. Pharmacogenomics. 2008;9:655-658.
35. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552. (Pubitemid 41070891)
36. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;(9):CD004332.
37. Hammarberg A, Jayaram-Lindström N, Beck O, et al. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology (Berl). 2009;205:53-62.
38. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61:905-912. (Pubitemid 39181080)
39. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685. (Pubitemid 36577440)
40. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1641-1651. (Pubitemid 47606653)
41. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849-1857.
42. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504-508.
43. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32:644-654. (Pubitemid 44412852)
44. Green AI, Drake RE, Brunette MF, et al. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164:402-408. (Pubitemid 46513152)
45. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441-449. (Pubitemid 30423220)
46. Soyka M, Aichmuller C, v Bardeleben U, et al. Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res. 2003;9:65-72. (Pubitemid 36351186)
47. Mueser KT, Noordsy DL, Fox L, et al. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict. 2003;12:242-252. (Pubitemid 36950973)
48. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl). 2004;172:291-297. (Pubitemid 38392322)
49. Tek C, Srihari V, Tek E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophr Res. 2008;106(2-3):373.
50. Kalyoncu A, Mirsal H, Pektas O, et al. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19:301-305. (Pubitemid 40694949)
51. Weisman RL. Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med. 2003;33:85-89. (Pubitemid 36927701)
52. Mason BJ, Kocsis JH, Ritvo EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;275:761-767. (Pubitemid 26087197)
53. McGrath PJ, Nunes EV, Stewart JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53:232-240.
54. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700-705. (Pubitemid 27344096)
55. Roy A. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics. Biol Psychiatry. 1998;44:633-637. (Pubitemid 28496692)
56. Gual A, Balcells M, Torres M, et al. Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized controlled trial. Alcohol Alcohol. 2003;38:619-625. (Pubitemid 37455862)
57. Moak DH, Anton RF, Latham PK, et al. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. J Clin Psychopharmacol. 2003;23:553-562. (Pubitemid 37443186)
58. Roy-Byrne PP, Pages KP, Russo JE, et al. Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2000;20:129-136. (Pubitemid 30202353)
59. Hernandez-Avila CA, Modesto-Lowe V, Feinn R, et al. Nefazodone treatment of comorbid alcohol dependence and major depression. Alcohol Clin Exp Res. 2004;28:433-440. (Pubitemid 38380746)
60. Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56:785-792. (Pubitemid 39539837)
61. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887-1896. (Pubitemid 38509503)
62. Torrens M, Fonseca F, Mateu G, et al. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend. 2005;78:1-22. (Pubitemid 40354172)
63. Petrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27:160-165. (Pubitemid 46594932)
64. Salloum IM, Cornelius JR, Thase ME, et al. Naltrexone utility in depressed alcoholics. Psychopharmacol Bull. 1998;34:111-115. (Pubitemid 28176311)
65. Lejoyeux M, Lehert P. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies. Alcohol Alcohol. 2011;46:61-67.
66. Pettinati HM, Oslin DW, Kampman KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry. 2010;167:668-675.
67. Frye MA, Salloum IM. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006;8:677-685. (Pubitemid 44824708)
68. Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37-45. (Pubitemid 40096069)
69. Brown ES, Carmody TJ, Schmitz JM, et al. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33:1863-1869.
70. Kranzler HR, Burleson JA, Del Boca FK, et al. Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry. 1994;51:720-731. (Pubitemid 24281783)
71. Tollefson GD, Montague-Clouse J, Tollefson SL. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol. 1992;12:19-26.
72. Malcolm R, Anton RF, Randall CL, et al. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992;16:1007-1013. (Pubitemid 23005139)
73. Brady KT, Sonne S, Anton RF, et al. Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res. 2005;29:395-401. (Pubitemid 40446132)
74. Petrakis IL, Poling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid post-traumatic stress disorder. Biol Psychiatry. 2006;60:777-783. (Pubitemid 44427772)
75. Thomas SE, Randall PK, Book SW, et al. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking? Alcohol Clin Exp Res. 2008;32:77-84. (Pubitemid 350293892)
76. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14:255-262. (Pubitemid 34013800)
77. Dierks MR, Jordan JK, Sheehan AH. Prazosin treatment of nightmares related to posttraumatic stress disorder. Ann Pharmacother. 2007;41:1013-1017. (Pubitemid 46917628)
78. Simpson TL, Saxon AJ, Meredith CW, et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. 2009;33:255-263.